Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Hum Mol Genet ; 30(10): 908-922, 2021 05 29.
Article in English | MEDLINE | ID: mdl-33822942

ABSTRACT

Mucolipidosis IV (MLIV) is an orphan disease leading to debilitating psychomotor deficits and vision loss. It is caused by loss-of-function mutations in the MCOLN1 gene that encodes the lysosomal transient receptor potential channel mucolipin1, or TRPML1. With no existing therapy, the unmet need in this disease is very high. Here, we showed that AAV-mediated CNS-targeted gene transfer of the human MCOLN1 gene rescued motor function and alleviated brain pathology in the MLIV mouse model. Using the AAV-PHP.b vector in symptomatic mice, we showed long-term reversal of declined motor function and significant delay of paralysis. Next, using self-complementary AAV9 clinical candidate vector, we showed that its intracerebroventricular administration in post-natal day 1 mice significantly improved motor function, myelination and reduced lysosomal storage load in the MLIV mouse brain. Based on our data and general advancements in the gene therapy field, we propose scAAV9-mediated CSF-targeted MCOLN1 gene transfer as a therapeutic strategy in MLIV.


Subject(s)
Genetic Therapy , Mucolipidoses/therapy , Nervous System Diseases/therapy , Transient Receptor Potential Channels/genetics , Animals , Brain/metabolism , Brain/pathology , Dependovirus/genetics , Disease Models, Animal , Humans , Loss of Function Mutation/genetics , Lysosomes/genetics , Lysosomes/pathology , Mice , Mucolipidoses/cerebrospinal fluid , Mucolipidoses/genetics , Mucolipidoses/pathology , Nervous System Diseases/cerebrospinal fluid , Nervous System Diseases/genetics , Nervous System Diseases/pathology
2.
Invest Ophthalmol Vis Sci ; 61(8): 49, 2020 07 01.
Article in English | MEDLINE | ID: mdl-32735323

ABSTRACT

Purpose: Leber hereditary optic neuropathy (LHON) is a genetic form of vision loss that occurs primarily owing to mutations in the nicotinamide adenine dinucleotide dehydrogenase (ND) subunits that make up complex I of the electron transport chain. LHON mutations result in the apoptotic death of retinal ganglion cells. We tested the hypothesis that gene therapy with the X-linked inhibitor of apoptosis (XIAP) would prevent retinal ganglion cell apoptosis and reduce disease progression in a vector-induced mouse model of LHON that carries the ND4 mutation. Methods: Adeno-associated virus (AAV) encoding full length hemagglutinin-tagged XIAP (AAV2.HA-XIAP) or green fluorescent protein (AAV2.GFP) was injected into the vitreous of DBA/1J mice. Two weeks later, the LHON phenotype was induced by AAV delivery of mutant ND4 (AAV2.mND4FLAG) to the vitreous. Retinal function was assessed by pattern electroretinography. Optic nerves were harvested at 4 months, and the effects of XIAP therapy on nerve fiber layer and optic nerve integrity were evaluated using immunohistochemistry, transmission electron microscopy and magnetic resonance imaging. Results: During LHON disease progression, retinal ganglion cell axons are lost. Apoptotic cell bodies are seen in the nuclei of astrocytes or oligodendrocytes in the optic nerve, and there is thinning of the optic nerve and the nerve fiber layer of the retina. At 4 months after disease onset, XIAP gene therapy protects the nerve fiber layer and optic nerve architecture by preserving axon health. XIAP also decreases nuclear fragmentation in resident astrocytes or oligodendrocytes and decreases glial cell infiltration. Conclusions: XIAP therapy improves optic nerve health and delays disease progression in LHON.


Subject(s)
Genetic Therapy/methods , Optic Atrophy, Hereditary, Leber , Optic Nerve , Retina , X-Linked Inhibitor of Apoptosis Protein/genetics , Animals , Apoptosis , Disease Models, Animal , Electroretinography/methods , Immunohistochemistry , Magnetic Resonance Imaging/methods , Mice , Optic Atrophy, Hereditary, Leber/genetics , Optic Atrophy, Hereditary, Leber/metabolism , Optic Atrophy, Hereditary, Leber/therapy , Optic Nerve/diagnostic imaging , Optic Nerve/physiopathology , Retina/diagnostic imaging , Retina/physiopathology , Retinal Ganglion Cells/metabolism , Treatment Outcome
3.
Hum Gene Ther ; 29(7): 771-784, 2018 07.
Article in English | MEDLINE | ID: mdl-29325457

ABSTRACT

Gene therapy is a promising approach in the treatment of inherited and common complex disorders of the retina. Preclinical and clinical studies have validated the use of adeno-associated viral vectors (AAV) as a safe and efficient delivery vehicle for gene transfer. Retinal pigment epithelium and rods-and to a lesser extent, cone photoreceptors-can be efficiently targeted with AAV. Other retinal cell types however are more challenging targets. The aim of this study was to characterize the transduction profile and efficiency of in silico designed, synthetic Anc80 AAVs for retinal gene transfer. Three Anc80 variants were evaluated for retinal targeting in mice and primates following subretinal delivery. In the murine retina Anc80L65 demonstrated high level of retinal pigment epithelium and photoreceptor targeting with comparable cone photoreceptor affinity compared to other AAVs. Remarkably, Anc80L65 enhanced transduction kinetics with visible expression as early as day 1 and steady state mRNA levels at day 3. Inner retinal tropism of Anc80 variants demonstrated distinct transduction patterns of Müller glia, retinal ganglion cells and inner nuclear layer neurons. Finally, murine findings with Anc80L65 qualitatively translated to the Rhesus macaque in terms of cell targets, levels and onset of expression. Our findings support the use of Anc80L65 for therapeutic subretinal gene delivery.


Subject(s)
Dependovirus/genetics , Genetic Therapy , Genetic Vectors/administration & dosage , Retina/metabolism , Retinal Diseases/therapy , Animals , Gene Transfer Techniques , Genetic Vectors/genetics , Humans , Macaca mulatta , Mice , Retina/drug effects , Retina/pathology , Retinal Cone Photoreceptor Cells/metabolism , Retinal Cone Photoreceptor Cells/pathology , Retinal Diseases/genetics , Retinal Diseases/pathology , Retinal Pigment Epithelium/metabolism , Retinal Pigment Epithelium/pathology , Retinal Rod Photoreceptor Cells/metabolism , Retinal Rod Photoreceptor Cells/pathology , Transduction, Genetic
4.
Front Neurosci ; 11: 503, 2017.
Article in English | MEDLINE | ID: mdl-28943836

ABSTRACT

Retinal gene therapy has come a long way in the last few decades and the development and improvement of new gene delivery technologies has been exponential. The recent promising results from the first clinical trials for inherited retinal degeneration due to mutations in RPE65 have provided a major breakthrough in the field and have helped cement the use of recombinant adeno-associated viruses (AAV) as the major tool for retinal gene supplementation. One of the key problems of AAV however, is its limited capacity for packaging genomic information to a maximum of around 4.8 kb. Previous studies have demonstrated that homologous recombination and/or inverted terminal repeat (ITR) mediated concatemerization of two overlapping AAV vectors can partially overcome the size limitation and help deliver larger transgenes. The aim of this study was to investigate and compare the use of different AAV dual-vector approaches in the mouse retina using a systematic approach comparing efficiencies in vitro and in vivo using a unique oversized reporter construct. We show that the hybrid approach relying on vector genome concatemerization by highly recombinogenic sequences and ITRs sequence overlap offers the best levels of reconstitution both in vitro and in vivo compared to trans-splicing and overlap strategies. Our data also demonstrate that dose and vector serotype do not affect reconstitution efficiency but a discrepancy between mRNA and protein expression data suggests a bottleneck affecting translation.

5.
Sci Rep ; 7: 45329, 2017 03 31.
Article in English | MEDLINE | ID: mdl-28361998

ABSTRACT

Widespread gene transfer to the retina is challenging as it requires vector systems to overcome physical and biochemical barriers to enter and diffuse throughout retinal tissue. We investigated whether exosome-associated adeno-associated virus, (exo-AAV) enabled broad retinal targeting following intravitreal (IVT) injection, as exosomes have been shown to traverse biological barriers and mediate widespread distribution upon systemic injection. We packaged an AAV genome encoding green fluorescent protein (GFP) into conventional AAV2 and exo-AAV2 vectors. Vectors were IVT injected into the eyes of adult mice. GFP expression was noninvasively monitored by fundus imaging and retinal expression was analyzed 4 weeks post-injection by qRT-PCR and histology. Exo-AAV2 outperformed conventional AAV2 in GFP expression based on fundus image analysis and qRT-PCR. Exo-AAV2 demonstrated deeper penetration in the retina, efficiently reaching the inner nuclear and outer plexiform, and to a lesser extent the outer nuclear layer. Cell targets were ganglion cells, bipolar cells, Müller cells, and photoreceptors. Exo-AAV2 serves as a robust gene delivery tool for murine retina, and the simplicity of production and isolation should make it widely applicable to basic research of the eye.


Subject(s)
Exosomes/genetics , Genetic Vectors/administration & dosage , Green Fluorescent Proteins/genetics , Retina/metabolism , Animals , Dependovirus/genetics , Gene Transfer Techniques , Intravitreal Injections , Male , Mice
6.
Hum Gene Ther ; 28(6): 482-492, 2017 06.
Article in English | MEDLINE | ID: mdl-28335619

ABSTRACT

Retinal detachment is an acute disorder in humans that is caused by trauma or disease, and it can often lead to permanent visual deficits that result from the death of photoreceptors in the retina. The final pathway for photoreceptor cell death is apoptosis and necroptosis. The X-linked inhibitor of apoptosis (XIAP) has been shown to block both of these cell death pathways. This study tested the effects of XIAP on photoreceptor survival in a feline model of retinal detachment. The study was performed in 12 cats, divided into two experimental groups. Six animals received a subretinal injection of adeno-associated virus (AAV) carrying XIAP, and six animals received AAV carrying green fluorescent protein (GFP) as a control. Three weeks after viral delivery, retinas were detached by injecting C3F8 gas into the subretinal space. Optical coherence tomography revealed that the retinal detachments resolved within 3-6 weeks as the gas was slowly resorbed. Analysis of histological sections through the plane of the detachment showed significant preservation of the photoreceptor layer in AAV-XIAP-treated animals compared to AAV-GFP-treated animals at 9 weeks after the detachment. XIAP-treated detached retinas were similar to intact controls. These studies support the potential for XIAP therapy in the treatment of human retinal detachment.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/metabolism , Retinal Cone Photoreceptor Cells/metabolism , Retinal Detachment/therapy , X-Linked Inhibitor of Apoptosis Protein/genetics , Animals , Apoptosis/genetics , Cats , Cell Line , Dependovirus/genetics , Dependovirus/metabolism , Disease Models, Animal , Fluorocarbons/administration & dosage , Gene Expression , Genes, Reporter , Genetic Vectors/administration & dosage , Genetic Vectors/chemistry , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Injections, Intraocular , Retinal Cone Photoreceptor Cells/pathology , Retinal Detachment/genetics , Retinal Detachment/metabolism , Retinal Detachment/pathology , Signal Transduction , Tomography, Optical Coherence , Transgenes , Treatment Outcome , X-Linked Inhibitor of Apoptosis Protein/metabolism
7.
Nat Biotechnol ; 35(3): 280-284, 2017 03.
Article in English | MEDLINE | ID: mdl-28165475

ABSTRACT

Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient, and clinically relevant delivery modalities. Here we demonstrate the safety and efficiency of Anc80L65, a rationally designed synthetic vector, for transgene delivery to the mouse cochlea. Ex vivo transduction of mouse organotypic explants identified Anc80L65 from a set of other adeno-associated virus (AAV) vectors as a potent vector for the cochlear cell targets. Round window membrane injection resulted in highly efficient transduction of inner and outer hair cells in mice, a substantial improvement over conventional AAV vectors. Anc80L65 round window injection was well tolerated, as indicated by sensory cell function, hearing and vestibular function, and immunologic parameters. The ability of Anc80L65 to target outer hair cells at high rates, a requirement for restoration of complex auditory function, may enable future gene therapies for hearing and balance disorders.


Subject(s)
Cochlea/physiology , Dependovirus/genetics , Genetic Therapy/methods , Genetic Vectors/genetics , Plasmids/genetics , Transduction, Genetic/methods , Animals , Cochlea/virology , Mice , Mice, Inbred C57BL , Plasmids/administration & dosage
8.
Adv Exp Med Biol ; 854: 315-21, 2016.
Article in English | MEDLINE | ID: mdl-26427427

ABSTRACT

We present an optimized surgical technique for feline retinal detachment which allows for natural re-attachment, reduces retinal scarring and vitreal bands, and allows central placement of the detachment in close proximity to the optic nerve. This enables imaging via Optical Coherence Tomography (OCT) and multifocal electroretinography (mfERG) analysis. Ideal detachment conditions involve a lensectomy followed by a three-port pars plana vitrectomy. A 16-20 % retinal detachment is induced by injecting 8 % C3F8 gas into the subretinal space in the central retina with a 42G cannula. The retinal detachment resolves approximately 6 weeks post-surgery. Imaging is enhanced by using a 7.5 and 20 diopter lens for OCT and mfERG fundus imaging, respectively, to compensate for the removed lens.


Subject(s)
Cat Diseases/surgery , Retina/surgery , Retinal Detachment/surgery , Vitrectomy/methods , Animals , Cat Diseases/diagnosis , Cat Diseases/physiopathology , Cats , Electroretinography , Fundus Oculi , Retina/pathology , Retinal Detachment/diagnosis , Retinal Detachment/physiopathology , Time Factors , Tomography, Optical Coherence , Treatment Outcome
9.
PLoS One ; 8(8): e70845, 2013.
Article in English | MEDLINE | ID: mdl-23990914

ABSTRACT

Lens regeneration studies in the adult newt suggest that molecular aspects of lens regeneration are complete within 5 weeks of lentectomy. However, very little is known about the optical properties of the regenerated lens. In an aquatic environment, the lens accounts for almost all of the refractive power of the eye, and thus, a fully functional lens is critical. We compared the optical properties of 9- and 26-week regenerated lenses in the red spotted newt, Notophthalmus viridescens, with the original lenses removed from the same eyes. At 9 weeks, the regenerated lenses are smaller than the original lenses and are histologically immature, with a lower density of lens proteins. The 9 week lenses have greater light transmission, but significantly reduced focal length and refractive index than the original lenses. This suggests that following 9 weeks of regeneration, the lenses have not recovered the functionality of the original lens. By 26 weeks, the transmission of light in the more mature lens is reduced, but the optical parameters of the lens have recovered enough to allow functional vision.


Subject(s)
Lens, Crystalline/physiology , Notophthalmus viridescens/physiology , Optics and Photonics , Regeneration , Vision, Ocular , Animals , Lens, Crystalline/surgery , Light , Ocular Physiological Phenomena , Refractometry , Retina/physiology , Time Factors
10.
Acad Med ; 88(6): 743-4, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23708596
11.
Acta Biomater ; 9(8): 7855-64, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23623991

ABSTRACT

Chitosan microparticles (CMPs) have previously been developed for topical applications to the eye, but their safety and efficacy in delivering proteins to the retina have not been adequately evaluated. This study examines the release kinetics of CMPs in vitro, and assesses their biocompatibility and cytotoxicity on retinal cells in vitro and in vivo. Two proteins were used in the encapsulation and release studies: BSA (bovine serum albumin) and tat-EGFP (enhanced green fluorescent protein fused to the transactivator of transcription peptide). Not surprisingly, the in vitro release kinetics were dependent on the protein encapsulated, with BSA showing higher release than tat-EGFP. CMPs containing encapsulated tat-EGFP were tested for cellular toxicity in photoreceptor-derived 661W cells. They showed no signs of in vitro cell toxicity at a low concentration (up to 1mgml(-1)), but at a higher concentration of 10mgml(-1) they were associated with cytotoxic effects. In vivo, CMPs injected into the subretinal space were found beneath the photoreceptor layer of the retina, and persisted for at least 8weeks. Similar to the in vitro studies, the lower concentration of CMPs was generally well tolerated, but the higher concentration resulted in cytotoxic effects and in reduced retinal function, as assessed by electroretinogram amplitudes. Overall, this study suggests that CMPs are effective long-term delivery agents to the retina, but the concentration of chitosan may affect cytotoxicity.


Subject(s)
Capsules/chemical synthesis , Chitosan/chemistry , Proteins/administration & dosage , Proteins/pharmacokinetics , Retina/metabolism , Animals , Capsules/administration & dosage , Cells, Cultured , Diffusion , Injections, Intraocular , Materials Testing , Metabolic Clearance Rate , Mice , Rats, Long-Evans , Retina/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...